BioSpace News Archive

- Full-year 2020 total net product revenue increased 84% to $62.9 million compared to 2019 - - 4Q20 total net product revenue increased 30% to $22.6 million compared to 3Q20 - - ANNOVERA ® net product revenue increased 42% for 4Q20 compared to 3Q20 - - Financing Agreement amended to update minimum net revenue covenants for remainder of loan; Company to pay down $50 million in debt -

Global Blood Therapeutics, Inc. will participate at the H.C. Wainwright Global Life Sciences Conference on Tuesday, March 9, 2021. A presentation by Ted W. Love, M.D., president and CEO of GBT, will be available at 7:00 a.m. ET.

- Negative Outcome on Primary Endpoint Measured by the Change from Baseline on the Positive and Negative Syndrome Scale/Negative Symptom Factor Score (PANSS NSFS) - Positive Outcome on Cognitive Assessment Secondary Endpoints Support Potential Further Clinical Development of Luvadaxistat - No New Safety Signals Compared to Previous Trials of Luvadaxistat

Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced its financial and operating results for the fourth quarter and full year of 2020. Fourth Quarter 2020 Highlights

Fusion to Leverage its Targeted Alpha Therapies (TAT) Expertise to Create FPI-2059, an Alpha-Emitting Radiopharmaceutical Targeting Solid Tumors

Cytocom, Inc. , a leading biopharmaceutical company creating second generation immune therapies, announced today that Mike Handley , President and Chief Executive Officer, will present at the H.C. Wainwright Global Life Sciences Conference taking place March 9, 2021 to March 10 , 2021.

Abbott (NYSE: ABT) announced today that a team of scientists has found an unusually high number of people in the Democratic Republic of Congo (DRC) who test positive for HIV antibodies, but have low to non-detectable viral load counts – without the use of antiretroviral treatment.

GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2020 Second half of 2021 remains the target for completion of enrollment of the GlycoMimetics-sponsored pivotal Phase 3 trial evaluating uproleselan in patients with relapsed/refractory acute myeloid leukemia (AML)

Halberd Corp. has recently produced a proprietary monoclonal antibody that has at least 20 times greater neutralizing affinity than their original antibody against the SARS-COV-2 Spike protein.

Zeel, a leading provider of trusted health and wellness services in the home and office, announced today a in-home testing milestone with the administration of over 5,000 COVID-19 PCR Swab Test to its patient network.